报告时间：2013年7月3日(星期三)，上午9：00

报告地点：生物楼一楼学术报告厅

报告人：ZHENG-RONG LU

M. Frank Rudy and Margaret Domiter Rudy Professor

of Case Western Reserve University, USA

报告摘要：

Tumor microenvironment plays a critical role in cancer angiogenesis, proliferation and metastasis. The unique tumor microenvironment is comprised of various cancer-related biomarkers, which are generally absent in normal tissues. Molecular imaging of the biomarkers in tumor microenvironment can provide accurate earlier detection and diagnosis of malignant tumors and non-invasive evaluation of anticancer therapeutic efficacy. Magnetic resonance imaging (MRI) is a powerful clinical imaging modality with high spatial resolution and no ionization radiation. MRI provides both anatomical and physiological information of soft tissues. Contrast enhanced MRI can produce high-resolution image contrast between diseased tissue and normal tissue and can measure the physiological properties of tumor tissue. We have designed and developed peptide targeted MRI contrast agents for detecting a cancer-related biomarker expressed in the extracellular matrix of malignant tumors, and polydisulfide-based biodegradable macromolecular MRI contrast agents for evaluating tumor angiogenesis and the efficacy of cancer therapies. The effectiveness of these novel MRI contrast agents has been validated in animal tumor models. The targeted contrast agents specifically bind to the biomarker in tumor extracellular matrix, resulting in strong and prolonged contrast enhancement in the tumor tissue, not in normal tissues. The biodegradable macromolecular contrast agents are effective for characterizing tumor angiogenesis and non-invasive evaluation of tumor response to cancer therapies, including angiogenesis therapy, with DCE-MRI.

报告人简介：CV_Zheng-Rong Lu.doc

报告联系人：1802组 谭明乾（9139）